Avinger Inc: insider trades · United States · SEC (Form 4)

About Avinger Inc

Avinger Inc. is a U.S.-listed medical device company traded on the NASDAQ in the United States. Founded in March 2007 and headquartered in Redwood City, California, the company designs, manufactures, and sells image-guided, catheter-based systems used by physicians to treat peripheral artery disease (PAD). Its core positioning is that of a niche vascular-intervention specialist, built around a differentiated technology platform rather than scale. Avinger’s Lumivascular platform combines optical coherence tomography (OCT) imaging with interventional catheters to provide real-time intravascular visualization during PAD treatment procedures. In its SEC filings, the company describes this as the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1506928/000143774924008711/avgr20231231_10k.htm?utm_source=openai)) The business model is centered on a mix of capital equipment and recurring disposables. The capital component is the Lightbox imaging console, while the consumable side includes single-use catheter families such as Ocelot, Tigereye, and the Pantheris atherectomy device family. This structure matters for investors because installed consoles help drive recurring catheter utilization, making adoption and procedure volume key operating variables. Avinger states that the long-term viability of the company is heavily dependent on the successful commercialization and continued development of Pantheris and that sales of Lumivascular products in the United States are expected to account for substantially all of its revenue for the foreseeable future. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1506928/000143774924008711/avgr20231231_10k.htm?utm_source=openai)) From a competitive standpoint, Avinger operates in a highly specialized and technically demanding segment of the medtech market, competing against larger healthcare companies with broader commercial reach and deeper balance sheets. Its investment case is therefore not one of market share dominance, but of technology-led differentiation, clinical adoption, and regulatory execution. The company’s scale remains small: for example, it reported third-quarter 2024 revenue of about $1.65 million, underscoring that it is still in a commercialization phase and highly sensitive to sales traction, reimbursement dynamics, and physician adoption. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1506928/000143774924033979/avgr20240930_10q.htm?utm_source=openai)) Recent corporate developments include a special stockholders’ meeting held on January 24, 2025, disclosed in an SEC Form 8-K, and continued capital-structure and financing-related activity referenced in 2024 SEC filings. For investors, Avinger remains a speculative micro-cap healthcare story: a NASDAQ-listed U.S. company whose upside depends on broader adoption of its Lumivascular platform, continued product development, and the ability to convert a differentiated clinical proposition into durable commercial growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1506928/000143774925001821/avgr20250124_8k.htm?utm_source=openai))